<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02505581</url>
  </required_header>
  <id_info>
    <org_study_id>2014-002345-21</org_study_id>
    <nct_id>NCT02505581</nct_id>
  </id_info>
  <brief_title>Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis</brief_title>
  <acronym>ORALEV</acronym>
  <official_title>Preoperative Oral Antibiotics and Surgical Site Infections in Colon Surgery Without Mechanical Bowel Preparation. A Prospective, Multicentre, Single Blinded, Randomized Trial (ORALEV Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Routine antibiotics for the intravenous and oral prophylaxis of colorectal surgery will be&#xD;
      used.&#xD;
&#xD;
      Experimental group: Patients undergoing elective colorectal surgery that involves, colonic&#xD;
      resection.&#xD;
&#xD;
      The antibiotic prophylaxis in this group will be composed of:&#xD;
&#xD;
      An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) and metronidazole (250mg /&#xD;
      8h, 3 doses) the day before surgery.&#xD;
&#xD;
      +&#xD;
&#xD;
      Control group: Patients undergoing elective colorectal surgery that involves, colonic&#xD;
      resection.&#xD;
&#xD;
      The antibiotic prophylaxis in this group will be composed of:&#xD;
&#xD;
      An intravenous antibiotic pattern of cefuroxime 1g and metronidazole 1,5gr during anesthetic&#xD;
      induction.&#xD;
&#xD;
      In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the&#xD;
      intraoperative time elongates more than three hours or there is an intraoperative bleeding&#xD;
      over 1000cc.&#xD;
&#xD;
      There won´t be a placebo treatment. Subject compliance will be evaluated according to the&#xD;
      usual practice in surgical care field&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">November 10, 2018</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound infection</measure>
    <time_frame>30 days</time_frame>
    <description>Superficial, deep, body-cavity This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 7 days</time_frame>
    <description>Hospital stay since colorectal surgery is done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct Adverse Drug Reactions</measure>
    <time_frame>24 hours since the drug is taken</time_frame>
    <description>Allergic reactions Intolerance&#xD;
•This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occlusive problems</measure>
    <time_frame>30 days from surgery</time_frame>
    <description>Intestinal occlusion, Anastomotic stenosis, Prolonged ileus(&gt;5days),.... Occlusive problems, Iatrogenic problems, Impaired healing ( Anastomotic leak rate , intestinal fistula , vesical fistula, peritonitis...) Bleeding problems, Cardiac complications, Nephro-urinary complications, Respiratory complications, Vascular Complications, Gastrointestinal complications, Neurological complications, Local complications...&#xD;
•This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iatrogenic problems</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Damage to structures such as ureters, bowel loops artery / iliac vein ....&#xD;
•This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impaired healing</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>This is a Clinical measure always supported by image tests.&#xD;
This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding problems</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Hemoperitoneum, abdominal hematoma,anastomotic bleeding ....&#xD;
•This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>acute myocardial infarction, angor pectoris , atrial fibrillation, acute pulmonary edema&#xD;
This is a Clinical measure supported by more specific tests if necessary.&#xD;
This morbidity problems are reported independently as a YES/NO variable&#xD;
Cardiologist report will be required for including this items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nephro-urinary complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Acute urinary retention, Acute renal failure, cystitis, pyelonephritis ...&#xD;
This is a Clinical measure supported by more specific tests if necessary.&#xD;
This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Pneumonia, Atelectasis, Pulmonary embolism, Respiratory distress syndrome ...&#xD;
This is a Clinical measure always supported by image .&#xD;
This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Deep venous thrombosis, phlebitis, thrombophlebitis, ...&#xD;
This is a Clinical measure supported by more specific test if necessary .&#xD;
This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Liver failure, gastrointestinal bleeding, severe malnutrition, ...&#xD;
This is a Clinical measure supported by blood test and further test if necessary&#xD;
This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Disorientation, cerebral vascular accident, ...&#xD;
This is a Clinical measure.&#xD;
This morbidity problems are reported independently as a YES/NO variable.&#xD;
Neurologist report will be required beyond disorientation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local infection</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Superficial, deep, body-cavity&#xD;
This is a Clinical measure supported by image if necessary&#xD;
This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Hematoma, seroma, evisceration&#xD;
This is a Clinical measure.&#xD;
This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">536</enrollment>
  <condition>Surgical Wound Infection</condition>
  <arm_group>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Only Parenteral prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extra dosage - cefuroxime (750mg) I.V</intervention_name>
    <description>In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc</description>
    <arm_group_label>Only Parenteral prophylaxis</arm_group_label>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colorectal Surgery</intervention_name>
    <description>Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)</description>
    <arm_group_label>Only Parenteral prophylaxis</arm_group_label>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin 750 mg oral</intervention_name>
    <description>An oral antibiotic pattern of ciprofloxacin (750 mg / 12h, 2 doses) the day before surgery.</description>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole 250 mg oral</intervention_name>
    <description>An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.</description>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime 1.5 g Intravenous</intervention_name>
    <description>An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.</description>
    <arm_group_label>Only Parenteral prophylaxis</arm_group_label>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole 1 g Intravenous</intervention_name>
    <description>An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.</description>
    <arm_group_label>Only Parenteral prophylaxis</arm_group_label>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting colonic pathology&#xD;
&#xD;
          -  The surgery is not contraindicated&#xD;
&#xD;
          -  Diagnosis of colorectal neoplasia or diverticular disease with surgical indication&#xD;
             (stenosis, chronic constipation, recurrent infections etc ..)&#xD;
&#xD;
          -  Indication of segmentary resection or total colectomy&#xD;
&#xD;
          -  Patients who agree to participate voluntarily in the study and signed an informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to participate in the study.&#xD;
&#xD;
          -  Patients undergoing mechanical colon preparation the day before surgery.&#xD;
&#xD;
          -  Patients with rectal cancer&#xD;
&#xD;
          -  Patients with intra-abdominal sepsis before surgery (abscess, diverticulitis).&#xD;
&#xD;
          -  Patients who received preoperative antibiotics for any reason in the two weeks prior&#xD;
             to surgery.&#xD;
&#xD;
          -  Patients with inflammatory bowel disease (ulcerative colitis, Crohn's disease and&#xD;
             indeterminate colitis)&#xD;
&#xD;
          -  Patients presenting allergy to the drugs under study.&#xD;
&#xD;
          -  Patients that will not strictly follow the assigned prophylaxis regimen&#xD;
&#xD;
          -  Patients undergoing urgent surgery (&lt;24h)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eloy Espin Basany, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitari Vall d'Hebron Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>January 12, 2020</last_update_submitted>
  <last_update_submitted_qc>January 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative Wound Infection</keyword>
  <keyword>Surgical Wound Infection</keyword>
  <keyword>Colorectal Surgery Infection Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

